This publication examines the innovation system in pharmaceutical biotechnology in eight OECD countries. Based on rich evidence, it draws policy recommendations to foster innovation in biopharmaceuticals advocating an integrated policy approach.
These guidelines offer principles and best practices for the licensing of genetic inventions used for the purpose of human health care.
While many countries have invested in the production of health technology assessment, evidence about its use in decision making is limited. This report analyses the barriers to, and facilitators of, evidence-based decision making in OECD health-care systems.
This workshop brought together a wide range of stakeholders, including officials of regulatory agencies, representatives of relevant regional or international organizations, researchers, patients’ organizations and representative from industry.
This paper provides an inventory of biotechnology data collection in India, including an assessment of how the need for biotechnology-related statistics is being addressed. It also presents an overview of the status of biotechnology in India, with a focus on the agricultural and health sectors.
This framework is intended to provide the basis for statistical compilation work within OECD member countries and those non-member countries wishing to adopt the standards.
This document sets out the provisional, single definition and list-based definitions of biotechnology.
English, , 1,579kb
In 2003 the OECD ran a large-scale survey on molecular genetic testing laboratory practices across 18 OECD countries. The survey was completed October 31, 2003. This report highlights short-term objectives of the survey.
Statistical work on biotechnology is carried out under the aegis of the OECD Working Party of National Experts on Science and Technology Indicators (NESTI). The above document gives the outcome of the 2004 experts' meeting.